ArticleFrontiers in pharmacology2026
Statins and reporting signals for amnesia: a pharmacovigilance analysis based on adverse event reporting database.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to explore the disproportionality reporting signals of amnesia associated with different statins based on a spontaneous adverse event database, so as to provide preliminary pharmacovigilance evidence for subsequent clinical safety evaluation and further pharmacoepidemiological verification. Materials and methods: This study employed pharmacovigilance analysis methods to monitor and analyze adverse event signals associated with seven commonly used statins. Additionally, subgroups were stratified by gender (male, female) and age (18, 45, and 65 years) to investigate the potential associations between statins and amnesia across different populations. Furthermore, a Weibull distribution analysis was used to assess the onset time of adverse events. Results: A total of 56,401 statin-related adverse event reports were included, among which 1,108 valid cases were coded as amnesia. Significant positive pharmacovigilance signals were identified for atorvastatin (n = 326, ROR = 2.82, 95% CI: 2.53-3.15, P < 0.001), simvastatin (n = 600, ROR = 4.94, 95% CI: 4.55-5.35, P < 0.001), pravastatin (n = 68, ROR = 4.77, 95% CI: 3.76-6.06, P < 0.001), and lovastatin (n = 26, ROR = 6.96, 95% CI: 4.73-10.24, P < 0.001). Subgroup analyses stratified by gender and age further identified heterogeneous pharmacovigilance signals across distinct populations. Moreover, Weibull distribution analysis also revealed unique distribution patterns among different statin agents. Conclusion: This study identified significant positive pharmacovigilance signals between certain statins and amnesia. The findings of this study provide preliminary disproportionality signals regarding statin-related amnesia, offering exploratory pharmacovigilance references for subsequent safety evaluation and further pharmacoepidemiological validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.